Ting Zhou

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Nan Chen, Wenfeng Fang, Jianhua Zhan et al. · Journal of Thoracic Oncology · 2015 · 686 citations · Full text

Medicine, Immunology, Oncology +17

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yunpeng Yang, Song Qu, Jingao Li et al. · The Lancet Oncology · 2021 · 449 citations

Medicine, Oncology, Pharmacology +12

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

Wenfeng Fang, Jianwei Zhang, Shaodong Hong et al. · Oncotarget · 2014 · 390 citations · Full text

Life Sciences, Cancer Biology, Oncology +16

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Nan Chen, Wenfeng Fang, Lin Zhong et al. · Cancer Immunology Immunotherapy · 2017 · 294 citations · Full text

Medicine, Immunology, Oncology +17

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)

Yunpeng Yang, Ting Zhou, Xiaozhong Chen et al. · Journal for ImmunoTherapy of Cancer · 2021 · 95 citations · Full text

Medicine, Oncology, Pharmacology +17